Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide plus metformin and intensive lifestyle intervention for remission of type 2 diabetes in obese adults
ChiCTR2200064171Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Southwest Medical University
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of semaglutide, metformin and chiglitazar in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) (3 arms), sponsored by Affiliated Hospital of Southwest Medical University. Primary endpoint: Glycated hemoglobin. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2200064171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064171.